

CURRICULUM VITAE



PERSONAL INFORMATION

Name	Giuseppe Ottone Cirulli
Telephone	(+39) 0382 503872
E-mail	g.cirulli@smatteo.pv.it
Office Address	Unit of Urology IRCCS Fondazione Policlinico San Matteo Piazzale Camillo Golgi, 2 27100 Pavia (PV) Italy

EDUCATION

2007 – 2012	Liceo Classico Nicola Zingarelli, Cerignola (FG), Italy High School Degree, (100/100)
2012 – 2018	Università Cattolica del Sacro Cuore, Rome, Italy Medical School Medical Degree (110/110 cum laude)
2019	Italian License to Medical Profession
2019 - 2024	Residency in Urology Vita-Salute San Raffaele University, Milan, Italy. Division of Oncology / Unit of Urology, IRCCS Ospedale San Raffaele Program director: Prof. Francesco Montorsi Supervisor: Prof. Alberto Briganti

TRAINING

2017 - 2019	Internship at the Department of Urology, Fondazione Policlinico Universitario IRCCS Agostino Gemelli, Rome, Italy Director: Prof. P.F. Bassi
September 2020 – February 2021	Urology Resident at the Department of Urology, Policlinico Sant'Anna, Brescia, Italy (Training network of the residency programme). Director: Dr. Najati Alrabi
March 2021 – August 2022	Urology Resident at the Department of Urology, Policlinico San Marco, Osio Sotto (BG), Italy. (Training network of the residency programme). Director: Dr. Camil Zaatar
March 2023 – March 2024	Research Fellow in Outcome Research Vattikuti Urology Institute, Center for Outcomes Research, Analysis, and Evaluation

(VCORE), Henry Ford Health System, Detroit, MI, USA
Directors: Dr Craig Roger, Dr. Firas Abdollah.

May 2024 – November 2024

Faisant Fonction d'Interne (FFI)
Department of Urology (Service d'Urologie), Pitié-Salpêtrière Hospital – Sorbonne University, Paris, France
Supervised by Prof. Morgan Rouprêt and Prof. Emmanuel Chartier-Kastler

CURRENT WORK POSITION

January 2025 – ongoing

Attending, full-staff Urologist
IRCCS Fondazione Policlinico San Matteo di Pavia (PV), Italy
Director: Prof. Richard Lawrence John Naspro

SCIENTIFIC AND MEDICAL SOCIETIES

03/2019 - ongoing

Italian Board of Physician and Surgeons

2021 – ongoing

SIU, Italian Society of Urology

2021 – ongoing

EAU, European Association of Urology

PERSONAL SKILLS AND COMPETENCES

Mother tongue

ITALIAN

Other language

English

Reading: Excellent; Writing: Good; Verbal: Good.

French

Reading: Excellent; Writing: Good; Verbal: Good.

Computer Skills

Electronic health record systems: Galileo (inpatient and outpatient EHR system), Sistema Informativo Ospedaliero (order entry), URI database, IMPAX (RIS/PACS software system)

Working knowledge of IT tools: Windows XP/Vista, Mac OS, Outlook, Microsoft Office software (Word, Excel, Access, etc.).

- 1) Mazzone E, Stabile A, Sorce G, Pellegrino F, Barletta F, Motterle G, Scuderi S, **Cirulli GO**, Cucchiara V, Brembilla G, Esposito A, Gandaglia G, Fossati N, De Cobelli F, Montorsi F, Karnes RJ, Guccini I, Briganti A. **Age and gleason score upgrading between prostate biopsy and radical prostatectomy: Is this still true in the multiparametric resonance imaging era?** Urol Oncol. 2021 Apr 14:S1078-1439(21)00124-1. doi: 10.1016/j.urolonc.2021.03.013. Epub ahead of print. PMID: 33865687.
- 2) Mazzone E, Stabile A, Pellegrino F, Basile G, Cignoli D, **Cirulli GO**, Sorce G, Barletta F, Scuderi S, Bravi CA, Cucchiara V, Fossati N, Gandaglia G, Montorsi F, Briganti A. **Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis.** Eur Urol Oncol. 2020 Dec 25:S2588-9311(20)30212-1. doi: 10.1016/j.euo.2020.12.004. Epub ahead of print. PMID: 33358543.
- 3) Stabile A, Mazzone E, **Cirulli GO**, De Cobelli F, Grummet J, Thoeny HC, Emberton M, Pokorny M, Pinto PA, Taneja SS. **Association Between Multiparametric Magnetic Resonance Imaging of the Prostate and Oncological Outcomes after Primary Treatment for Prostate Cancer: A Systematic Review and Meta-analysis.** Eur Urol Oncol. 2020 Dec 28:S2588-9311(20)30204-2. doi: 10.1016/j.euo.2020.11.008. Epub ahead of print. PMID: 33384275.
- 4) Martini A, Fallara G, Pellegrino F, **Cirulli GO**, Larcher A, Necchi A, Montorsi F, Capitanio U. **Neoadjuvant and adjuvant immunotherapy in renal cell carcinoma.** World J Urol. 2021 May;39(5):1369-1376. doi: 10.1007/s00345-020-03550-z. Epub 2021 Jan 1. PMID: 33386494.
- 5) Bandini M, Barbagli G, Leni R, **Cirulli GO**, Basile G, Balò S, Montorsi F, Sansalone S, Salonia A, Briganti A, Butnaru D, Lazzeri M. **Assessing in-hospital morbidity after urethroplasty using the European Association of Urology Quality Criteria for standardized reporting.** World J Urol. 2021 Apr 15. doi: 10.1007/s00345-021-03692-8. Epub ahead of print. PMID: 33855598.
- 6) Stabile A, Barletta F, Motterle G, Pellegrino F, Sorce G, Mazzone E, Scuderi S, **Cirulli GO**, Cucchiara V, Esposito A, Gandaglia G, Fossati N, De Cobelli F, Montorsi F, Karnes RJ, Briganti A. **Optimizing prostate-targeted biopsy schemes in men with multiple mpMRI visible lesions: should we target all suspicious areas? Results of a two institution series.** Prostate Cancer Prostatic Dis. 2021 May 3. doi: 10.1038/s41391-021-00371-y. Epub ahead of print. PMID: 33941867.
- 7) Bandini M, Ahmed M, Basile G, Watkin N, Master V, Zhu Y, Prakash G, Rodriguez A, Ssebakumba MK, Leni R, **Cirulli GO**, Ayres B, Compitello R, Pederzoli F, Joshi PM, Kulkarni SB, Montorsi F, Sonpavde G, Necchi A, Spiess PE. **A global approach to improving penile cancer care.** Nat Rev Urol. 2022 Apr;19(4):231-239. doi: 10.1038/s41585-021-00557-y. Epub 2021 Dec 22. Erratum in: Nat Rev Urol. 2022 Jan 18;; PMID: 34937881; PMCID: PMC8693593.
- 8) Bandini M, Ahmed M, Basile G, Watkin N, Master V, Zhu Y, Prakash G, Rodriguez A, Ssebakumba MK, Leni R, **Cirulli GO**, Ayres B, Compitello R, Pederzoli F, Joshi PM, Kulkarni SB, Montorsi F, Sonpavde G, Necchi A, Spiess PE. **Author Correction: A global approach to improving penile cancer care.** Nat Rev Urol. 2022 Apr;19(4):253. doi: 10.1038/s41585-022-00569-2. Erratum for: Nat Rev Urol. 2022 Apr;19(4):231-239. PMID: 35043020; PMCID: PMC9119274.
- 9) Barletta F, Stabile A, Mazzone E, Brembilla G, Sorce G, Pellegrino F, Scuderi S, Cannoletta D, **Cirulli GO**, Cucchiara V, Gandaglia G, De Cobelli F, Montorsi F, Briganti A. **How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series.** Urol Oncol. 2022 Mar;40(3):103.e17-103.e24. doi: 10.1016/j.urolonc.2021.09.015. Epub 2021 Oct 27. PMID: 34688534.

- 10) Mazzone E, Gandaglia G, Stabile A, Bravi CA, Barletta F, Scuderi S, **Cirulli GO**, Fossati N, Cucchiara V, Raggi D, Necchi A, Montorsi F, Briganti A. **Not All Adverse Pathology Features Are Equal: Identifying Optimal Candidates for Adjuvant Radiotherapy Among Patients With Adverse Pathology at Radical Prostatectomy.** J Urol. 2022 Jul 5;101097JU0000000000002855. doi: 10.1097/JU.0000000000002855. Epub ahead of print. PMID: 35830554.
- 11) Pellegrino A, **Cirulli GO**, Mazzone E, Barletta F, Scuderi S, de Angelis M, Rosiello G, Gandaglia G, Montorsi F, Briganti A, Stabile A. **Focal therapy for prostate cancer: what is really needed to move from investigational to valid therapeutic alternative?-a narrative review.** Ann Transl Med. 2022 Jul;10(13):755. doi: 10.21037/atm-22-50. PMID: 35957731; PMCID: PMC9358522.
- 12) Barletta F, Mazzone E, Stabile A, Scuderi S, Brembilla G, de Angelis M, **Cirulli GO**, Cucchiara V, Gandaglia G, Karnes RJ, Roupret M, De Cobelli F, Montorsi F, Briganti A. **Assessing the need for systematic biopsies in addition to targeted biopsies according to the characteristics of the index lesion at mpMRI. Results from a large, multi-institutional database.** World J Urol. 2022 Nov;40(11):2683-2688. doi: 10.1007/s00345-022-04155-4. Epub 2022 Sep 23. PMID: 36149448.
- 13) Stabile A, Sorce G, Barletta F, Brembilla G, Mazzone E, Pellegrino F, Cannoletta D, **Cirulli GO**, Gandaglia G, De Cobelli F, Montorsi F, Briganti A. **Impact of prostate MRI central review over the diagnostic performance of MRI-targeted biopsy: should we routinely ask for an expert second opinion?** World J Urol. 2023 Nov;41(11):3231-3237. doi: 10.1007/s00345-023-04365-4. Epub 2023 Mar 21. PMID: 36943477.
- 14) Leni R, Gandaglia G, Stabile A, Mazzone E, Pellegrino F, Scuderi S, Robesti D, Barletta F, **Cirulli GO**, Cucchiara V, Zaffuto E, Dehò F, Montorsi F, Briganti A. **Is Active Surveillance an Option for the Management of Men with Low-grade Prostate Cancer and a Positive Family History? Results from a Large, Single-institution Series.** Eur Urol Oncol. 2023 Oct;6(5):493-500. doi: 10.1016/j.euo.2023.02.014. Epub 2023 Mar 31. PMID: 37005213.
- 15) Pellegrino A, Gandaglia G, de Angelis M, Fallara G, Mazzone E, Stabile A, Pellegrino F, Robesti D, Leni R, Scuderi S, Cucchiara V, **Cirulli GO**, Barletta F, Montorsi F, Briganti A. **Oncological and perioperative outcomes of surgery with or without metastasis-directed therapy as part of a multimodal treatment in men with de-novo oligometastatic prostate cancer.** World J Urol. 2023 Aug;41(8):2069-2076. doi: 10.1007/s00345-023-04460-6. Epub 2023 Jun 16. PMID: 37326656.
- 16) **Cirulli GO**, Corsi N, Rakic I, Stephens A, Chiarelli G, Finati M, Davis M, Tinsley S, Sood A, Buffi N, Lughezzani G, Carrieri G, Salonia A, Briganti A, Montorsi F, Rogers C, Abdollah F. **Impact of lymphovascular invasion on survival in surgically treated upper tract urothelial carcinoma: a nationwide analysis.** BJU Int. 2023 Dec 14. doi: 10.1111/bju.16258. Epub ahead of print. PMID: 38097533.
- 17) Pellegrino F, Stabile A, Sorce G, Mazzone E, Cannoletta D, **Cirulli GO**, Quarta L, Leni R, Robesti D, Brembilla G, Gandaglia G, De Cobelli F, Montorsi F, Briganti A. **Variability of mpMRI diagnostic performance according to the upfront individual patient risk of having clinically significant prostate cancer.** Prostate. 2023 Dec 27. doi: 10.1002/pros.24665. Epub ahead of print. PMID: 38149793.
- 18) Pellegrino F, Stabile A, Sorce G, Quarta L, Robesti D, Cannoletta D, **Cirulli G**, Barletta F, Scuderi S, Mazzone E, de Angelis M, Brembilla G, De Cobelli F, Salonia A, Montorsi F, Briganti A, Gandaglia G. **Added Value of Prostate-specific Antigen Density in Selecting Prostate Biopsy Candidates Among Men with Elevated Prostate-specific Antigen and PI-RADS ≥ 3 Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: A Systematic Assessment by PI-RADS Score.** Eur Urol Focus. 2023 Oct 19:S2405-4569(23)00223-7. doi: 10.1016/j.euf.2023.10.006. Epub ahead of print. PMID: 37865591.

- 19) Arora S, Chen I, Bronkema C, Chiarelli G, Finati M, **Cirulli GO**, Majdalany SE, Rakic I, Sood A, Trinh QD, Rogers CG, Peabody JO, Menon M, Abdollah F. **Admission Rates, Healthcare Utilization, and Inpatient Cost of Radiation Cystitis in the United States.** *Urology*. 2023 Dec 29:S0090-4295(23)01110-X. doi: 10.1016/j.urology.2023.12.008. Epub ahead of print. PMID: 38160761.
- 20) Chiarelli G, Davis M, Stephens A, **Cirulli GO**, Finati M, Corsi NJ, Sood A, Tinsley S, Carrieri G, Briganti A, Montorsi F, Lughezzani G, Buffi N, Rogers C, Abdollah F. **Comparison of patient background between a real-world North American cohort and the Göteborg-2 trial.** *Int J Urol*. 2024 Feb 9. doi: 10.1111/iju.15415. Epub ahead of print. PMID: 38334296.
- 21) Corsi NJ, Stephens A, Finati M, Malchow T, Morrison C, Davis M, Hares K, Corsi MP, Arora S, Chiarelli G, **Cirulli GO**, Autorino R, Sood A, Rogers C, Abdollah F. **Testing the external validity of the POUT III trial (adjuvant platinum-based chemotherapy in upper tract urothelial carcinoma) in a North American cohort.** *Urol Oncol*. 2024 Mar 23:S1078-1439(24)00051-6. doi: 10.1016/j.urolonc.2024.01.035. Epub ahead of print. PMID: 38522975.
- 22) Chiarelli G, Stephens A, Finati M, **Cirulli GO**, Beatrice E, Filipas DK, Arora S, Tinsley S, Bhandari M, Carrieri G, Trinh QD, Briganti A, Montorsi F, Lughezzani G, Buffi N, Rogers C, Abdollah F. **Adequacy of prostate cancer prevention and screening recommendations provided by an artificial intelligence-powered large language model.** *Int Urol Nephrol*. 2024 Apr 2. doi: 10.1007/s11255-024-04009-5. Epub ahead of print. PMID: 38564079.
- 23) Tinsley SA, Finati M, Stephens A, Chiarelli G, **Cirulli GO**, Williams E, Morrison C, Richard C, Hares K, Sood A, Buffi N, Lughezzani G, Bettocchi C, Salonia A, Briganti A, Montorsi F, Carrieri G, Rogers C, Abdollah F. **Race has no impact on prostate cancer-specific mortality, when comparing patients with similar risk of other-cause mortality: An analysis of a population-based cohort.** *Cancer*. 2024 Sep 15;130(18):3157-3169. doi: 10.1002/cncr.35386. Epub 2024 May 28. PMID: 38804713.
- 24) Finati M, Davis M, Stephens A, Chiarelli G, **Cirulli GO**, Morrison C, Affas R, Sood A, Buffi N, Lughezzani G, Briganti A, Montorsi F, Carrieri G, Rogers C, Vickers AJ, Abdollah F. **The Role of Baseline Prostate-specific Antigen Value Prior to Age 60 in Predicting Lethal Prostate Cancer: Analysis of a Contemporary North American Cohort.** *Eur Urol Oncol*. 2024 Jul 10:S2588-9311(24)00172-X. doi: 10.1016/j.euo.2024.06.014. Epub ahead of print. PMID: 38991891.
- 25) **Cirulli GO**, Davis M, Stephens A, Chiarelli G, Finati M, Corsi N, Williams E, Affas R, Sood A, Buffi N, Lughezzani G, Carrieri G, Salonia A, Briganti A, Montorsi F, Rogers C, Abdollah F. **Impact of Prostate-Specific Antigen Screening Pattern on Prostate Cancer Mortality Among Non-Hispanic Black and Non-Hispanic White Men: A Large, Urban Health System Cohort Analysis.** *J Urol*. 2024 Oct;212(4):560-570. doi: 10.1097/JU.0000000000004118. Epub 2024 Jul 30. PMID: 39079152.
- 26) Tinsley SA, Arora S, Stephens A, Finati M, Chiarelli G, **Cirulli GO**, Morrison C, Richard C, Hares K, Rogers CG, Abdollah F. **The impact of cannabis use disorder on urologic oncologic surgery morbidity, length of stay, and inpatient cost: analysis of the National Inpatient Sample from 2003 to 2014.** *World J Urol*. 2024 Aug 2;42(1):465. doi: 10.1007/s00345-024-05151-6. PMID: 39090376.
- 27) Finati M, Stephens A, Chiarelli G, **Cirulli GO**, Tinsley S, Wang Y, Sood A, Buffi N, Lughezzani G, Salonia A, Briganti A, Montorsi F, Busetto GM, Carrieri G, Rogers C, Abdollah F. **Radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer: Analysis of an other-cause mortality matched cohort.** *Urol Oncol*. 2024 Sep 5:S1078-1439(24)00572-6. doi: 10.1016/j.urolonc.2024.08.001. Epub ahead of print. PMID: 39242301.
- 28) Finati M, Corsi NJ, Stephens A, Chiarelli G, **Cirulli GO**, Davis M, Tinsley S, Sood A, Buffi N, Lughezzani G, Salonia A, Briganti A, Montorsi F, Bettocchi C, Carrieri G, Rogers C, Abdollah F. **The Impact of Radical Prostatectomy Versus Radiation**

Therapy on Cancer-Specific Mortality for Nonmetastatic Prostate Cancer: Analysis of an Other-Cause Mortality Matched Cohort. Clin Genitourin Cancer. 2024 Aug 13;22(6):102201. doi: 10.1016/j.clgc.2024.102201. Epub ahead of print. PMID: 39243664.

29) **Cirulli GO**, Davis M, Stephens A, Chiarelli G, Finati M, Chase M, Tinsley S, Arora S, Sood A, Lughezzani G, Buffi N, Carrieri G, Salonia A, Briganti A, Montorsi F, Rogers C, Abdollah F. **Midlife baseline prostate-specific antigen, velocity, and doubling time association with lethal prostate cancer and mortality.** Cancer. 2025 Jan 1;131(1):e35563. doi: 10.1002/cncr.35563. Epub 2024 Oct 8. PMID: 39377255.

30) Finati M, Morrison C, Stephens A, Chiarelli G, **Cirulli GO**, Tinsley S, Davis M, Sood A, Buffi N, Lughezzani G, Salonia A, Briganti A, Montorsi F, Busetto GM, Bettocchi C, Rogers C, Carrieri G, Abdollah F. **Association of race with incidence, characteristics, and mortality from incidental prostate cancer: Analysis of two North American contemporary cohorts.** Prostate. 2025 Jan;85(1):82-89. doi: 10.1002/pros.24803. Epub 2024 Oct 28. PMID: 39465565.

31) Tinsley SA, Stephens A, Finati M, Chiarelli G, **Cirulli GO**, Morrison C, Richard C, Hares K, Lutchka J, Sood A, Buffi N, Lughezzani G, Bettocchi C, Salonia A, Briganti A, Montorsi F, Carrieri G, Rogers C, Abdollah F. **Surgery versus radiation for clinically positive nodal prostate cancer in an other cause mortality risk weighted cohort.** Int Urol Nephrol. 2025 Mar;57(3):825-837. doi: 10.1007/s11255-024-04253-9. Epub 2024 Nov 11. PMID: 39528898.

32) Finati M, Stephens A, **Cirulli GO**, Chiarelli G, Tinsley S, Morrison C, Sood A, Buffi N, Lughezzani G, Salonia A, Briganti A, Montorsi F, Busetto GM, Rogers C, Carrieri G, Abdollah F. **Association of race and area of deprivation index with prostate cancer incidence and lethality: results from a contemporary North American cohort.** JNCI Cancer Spectr. 2024 Nov 1;8(6):pkae112. doi: 10.1093/jncics/pkae112. PMID: 39576690; PMCID: PMC11658688.

33) Chiarelli G, Stephens A, Finati M, **Cirulli GO**, Tinsley S, Wang Y, Kolanukuduru K, Sood A, Carrieri G, Briganti A, Montorsi F, Lughezzani G, Buffi N, Rogers C, Abdollah F. **Active surveillance follow-up for prostate cancer: from guidelines to real-world clinical practice.** World J Urol. 2024 Nov 26;42(1):646. doi: 10.1007/s00345-024-05373-8. PMID: 39589591.

34) Chiarelli G, Davis M, Stephens A, Finati M, **Cirulli GO**, Morrison C, Sood A, Carrieri G, Briganti A, Montorsi F, Lughezzani G, Buffi N, Rogers C, Abdollah F. **Racial Disparities in Future Development of Lethal Prostate Cancer Based on Midlife Baseline Prostate-Specific Antigen.** Prostate. 2025 Mar;85(4):354-363. doi: 10.1002/pros.24834. Epub 2024 Dec 9. PMID: 39651707.

35) **Cirulli GO**, Stephens A, Chiarelli G, Finati M, Bertini A, Chase M, Tinsley S, Arora S, Sood A, Lughezzani G, Buffi N, Carrieri G, Salonia A, Briganti A, Montorsi F, Rogers C, Abdollah F. **Comparing PSA Screening Patterns and Their Role as Predictor of Prostate Cancer Diagnosis: Analysis of a Contemporary North American Cohort.** Prostate. 2025 May;85(6):531-540. doi: 10.1002/pros.24856. Epub 2025 Jan 27. PMID: 39869547.

36) Barletta F, Bandini M, **Cirulli GO**, Zaurito P, Lucianò R, Giannese F, Scotti GM, Oneto C, Tenace N, Scarfò F, Morelli MJ, Lazarevic D, De Cobelli F, Ponzoni M, Doglioni C, Tonon G, Gandaglia G, Montorsi F, Briganti A. **DNA methylation alterations in prostate cancer: from diagnosis to treatment.** Transl Androl Urol. 2025 Feb 28;14(2):454-462. doi: 10.21037/tau-24-382. Epub 2025 Feb 25. PMID: 40114836; PMCID: PMC11921382.

37) Zattoni F, Gandaglia G, Marra G, Carletti F, Kasivisvanathan V, Ploussard G, Fazekas T, Martini A, Olivier J, Chiu PK, Valerio M, Marquis A, Gontero P, Guo H, Zhuang J, Barletta F, Leni R, **Cirulli G**, Kretschmer A, Apfelbeck M, Kesch C, Rajwa P, Giganti F, den Bergh RV, Dal Moro F, Briganti A, Novara G; EAU-YAU Prostate Cancer Working Party. **Targeting All Multiple Magnetic Resonance Imaging**

Prostate Lesions Does Not Enhance Cancer Detection: Insights from the YAU Prostate Cancer Group. Eur Urol Open Sci. 2025 Apr 7;75:61-68. doi: 10.1016/j.euros.2025.03.008. PMID: 40256662; PMCID: PMC12008533.

38) Finati M, **Cirulli GO**, Chiarelli G, Stephens A, Tinsley S, Morrison C, Sood A, Buffi N, Lughezzani G, Salonia A, Briganti A, Montorsi F, Bettocchi C, Carrieri G, Rogers C, Abdollah F. **The Role of Cytoreductive Nephrectomy in Contemporary Metastatic Renal Cell Carcinoma: An Other-Cause Mortality Match Population-Based Study.** Clin Genitourin Cancer. 2025 Aug;23(4):102374. doi: 10.1016/j.clgc.2025.102374. Epub 2025 May 13. PMID: 40514268.

39) Bertini A, **Cirulli GO**, Stephens A, Finocchiaro A, Viganò S, Lughezzani G, Buffi N, Di Trapani E, Ficarra V, Salonia A, Briganti A, Montorsi F, Sood A, Rogers C, Abdollah F. **Socioeconomic disparities in prostate cancer screening: the impact of the Area Deprivation Index on PSA screening frequency.** BJU Int. 2025 Jul 30. doi: 10.1111/bju.16875. Epub ahead of print. PMID: 40736416.

40) Bertini A, **Cirulli GO**, Stephens A, Finocchiaro A, Viganò S, Lughezzani G, Buffi N, Ficarra V, Salonia A, Briganti A, Montorsi F, Sood A, Rogers C, Abdollah F. **Reply to 'Comment on Bertini et al.: area deprivation and PSA screening disparities' and 'Comment on socioeconomic disparities in prostate cancer screening: the impact of the Area Deprivation Index on PSA screening frequency'.** BJU Int. 2025 Sep 4. doi: 10.1111/bju.16924. Epub ahead of print. PMID: 40905572.

CONFERENCE SPEAKER

European Association of Urology, 36th Annual Congress, 08-12 July 2021.

Relator of the posters:

- "Balancing efficacy and toxicity of docetaxel in patients with metastatic castration-resistant prostate cancer. Results from a pooled analysis of three prospective randomized trials".
- "The obesity paradox in metastatic castration resistant prostate cancer".

American Urological Association, (AUA) Annual Meeting, 10-13 September 2021.

Relator of the posters:

- "Balancing efficacy and toxicity of docetaxel in patients with metastatic castration-resistant prostate cancer. Results from a pooled analysis of three prospective randomized trials".
- "The obesity paradox in metastatic castration resistant prostate cancer".

Società Italiana di Urologia, 94th Annual Congress, 16-19 October 2021.

Relator of the posters:

- "PET/CT Allows for a reliable assessment of the real nodal burden in clinically node-positive prostate cancer patients candidate for radical prostatectomy: Results from a multi-institutional series".
- "Added value of radiological tumor stage in predicting early oncological outcomes in prostate cancer patients undergoing radical prostatectomy within clinical stage: A stage by stage analysis".

American Urological Association, (AUA) Annual Meeting, 13-16 May 2022.

Relator of the posters:

- Not all adverse pathology features are equal: identifying optimal candidates for adjuvant radiotherapy among patients with adverse pathology at radical prostatectomy.
- Which Patients With cN1 disease at PET/CT Are affected by systemic disease? Implications for tailored treatment approaches based on a large multi-institutional series.
- The role of 68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI in the primary staging of high-risk Prostate Cancer patients undergoing radical prostatectomy. Preliminary results of a prospective, single center study.
- The association between the introduction of mpMRI in prostate cancer diagnostic pathway and biochemical recurrence after RP. Result from a large single-institutional series.
- The Risk of Recurrence in cN1 Prostate Cancer Patients treated with radical

prostatectomy Varies According to the type Preoperative Staging. A comparison between 68Ga-PSMA-PET versus Conventional Imaging in a large, Multi-institutional Study.

European Association of Urology, 38th Annual Congress, March 2022.

Relator of the poster: A Novel Model Integrating Clinical, mp-MRI, and Epigenomic Features to Predict Lymph Node Invasion in Prostate Cancer Patients Undergoing Radical Prostatectomy and Pelvic Lymph Node Dissection

American Urological Association, (AUA) Annual Meeting, May 2023.

Relator of the posters:

- A Novel Model Integrating Clinical, mp-MRI, and Epigenomic Features to Predict Lymph Node Invasion in Prostate Cancer Patients Undergoing Radical Prostatectomy and Pelvic Lymph Node Dissection
- Validation of Novel Preoperative Risk Categories On The Prediction of Clinical Recurrence In Patients Candidate To Radical Prostatectomy For clinically localized Prostate Cancer. Results of a large, multi-institutional series.

European Association of Urology, 39th Annual Congress, April 2024

Relator of the posters:

- Comparing PSA Screening Patterns and their role as predictor of Prostate Cancer Diagnosis: analysis of a contemporary North American cohort.
- Impact of Prostate-Specific Antigen screening pattern on prostate cancer-mortality Among Non-Hispanic Black and Non-Hispanic White men: A large, urban health system cohort analysis.
- Superiority of Midlife Baseline Prostate-Specific Antigen value over PSA doubling time and velocity in the prediction of lethal prostate cancer development, and mortality: a system wide analysis of a racially diverse North American cohort
- Testing Free PSA Percentage as a tool in predicting future risk of developing Prostate Cancer: a system wide analysis of a contemporary North American cohort.
- Impact of lymphovascular invasion on survival of surgically treated patients with Upper Tract Urothelial Carcinoma: a nationwide analysis

Date, 10/09/2025